Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Carbapenem-Based Antibiotics Industry?

The market size for carbapenem-based antibiotics has been on a steady upward trend in the past few years. The market evaluation will increase from $4.6 billion in 2024 to $4.78 billion in 2025, reflecting a compound annual growth rate (CAGR) of 3.8%. Factors contributing to this growth during the historical period include epidemic and pandemic outbreaks, increases in chronic illnesses, enhancements in healthcare infrastructure, swift urbanization, natural calamities, and health-related emergencies.

The market for carbapenem-based antibiotics is projected to experience substantial growth in the coming years, eventually reaching a size of “$5.97 billion in 2029 with a compound annual growth rate (CAGR) of 5.7%. This projected growth can be credited to several factors, such as the rising occurrence of infections acquired in hospitals, the notification of multi-drug resistant strains, an increasing elderly population, an uptick in surgical procedures, the spread of infectious diseases, and changes in demographics. Notable trends foreseen for this period involve enhancements in supply chain resilience and security, the development of alternative treatments, a shift towards outpatient settings, increased understanding of antimicrobial stewardship, and the use of precision medicine techniques.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12035&type=smp

What Forces Are Driving The Growth Of The Carbapenem-Based Antibiotics Industry?

The surge in bacterial infection cases is predicted to fuel the advancement of the carbapenem-based antibiotics market. Bacterial infections, brought about by microscopic organisms capable of infiltrating the body and triggering various diseases and symptoms, are treatable with carbapenem-based antibiotics. These antibiotics are particularly effective against serious or multi-drug resistant bacterial infections, including those triggered by gram-positive and gram-negative bacteria. For instance, as per the Centers for Disease Control and Prevention, a US-based government body’s report in July 2024, throughout 2023, CIDTs diagnosed 78% of all bacterial infections in the historic catchment area, which includes 46% diagnosed using only CIDTs. Therefore, the escalating occurrence of bacterial infections stimulates the growth of the carbapenem-based antibiotics market.

What Is The Overview Of Market Segmentation In The Carbapenem-Based Antibiotics Industry?

The carbapenem-based antibiotics market covered in this report is segmented –

1) By Type: Meropenem, Imipenem, Doripenem, Tebipenem, Other Types

2) By Indication: Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin And Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Meropenem: Meropenem Injection, Meropenem and Vaborbactam Combination, Meropenem for Pediatric Use

2) By Imipenem: Imipenem and Cilastatin Combination, Imipenem and Relebactam Combination, Imipenem Monotherapy

3) By Doripenem: Doripenem Injection, Doripenem for Complicated Infections

4) By Tebipenem: Tebipenem for Oral Administration, Tebipenem Pediatric Formulations, Tebipenem for Resistant Infections

5) By Other Types: Ertapenem, Panipenem, Faropenem, Combinations with Beta-Lactamase Inhibitors

What Are The Leading Trends And Opportunities In The Carbapenem-Based Antibiotics Sector?

Product advancement is a growing trend in the carbapenem-based antibiotics market. Major industry players are striving to maintain their edge through innovation. For example, in August 2024, the National Health Service, a government department in the UK, initiated an innovative subscription scheme in collaboration with the pharmaceutical industry to fight antimicrobial resistance (AMR). Unveiled on August 12, 2024, the model enables pharmaceutical manufacturers to earn fixed yearly fees up to £20 million per drug, independent of prescription volume, eliminating motives for excessive usage. The programme, estimated to be worth around £1.9 billion over 16 years, intends to stimulate the creation of new antibiotics by assuring economic sustainability for pharmaceutical firms. This approach comes after a successful pilot stage and forms part of the UK’s comprehensive strategy to confront AMR, a severe global health risk that could result in millions of fatalities by 2050 if not tackled. The NHS will prioritise products aimed at critical pathogens as determined by the World Health Organization, underscoring its dedication to sensible antibiotic management whilst promoting antibiotic innovation.

Who Are The Primary Players Operating Across The Global Carbapenem-Based Antibiotics Market?

Major companies operating in the carbapenem-based antibiotics market include Pfizer Inc., Merck & Co. Inc., Fresenius Kabi LLC, GlaxoSmithKline Plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Acurx Pharmaceuticals LLC, Daewoong Pharmaceutical Co. Ltd., CeramTec GmbH, ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report

Which Region Offers The Most Growth Potential For The Carbapenem-Based Antibiotics Market Through 2029?

North America was the largest region in the Carbapenem-Based Antibiotics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12035&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model